Michael Milone
Associate Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Michael Milone is an Associate Professor at the University of Pennsylvania, USA. His research primarily focuses on the development and implications of Concept CARs, as highlighted in his recent publications. With a strong commitment to advancing understanding in his field, Professor Milone contributes significantly to academic discourse and innovation.
Articles (3)
Year:
2025
Supplemental tables: (1) Subject characteristics. (2) Cytogenetic profiles and high-risk features. (3) Prior treatment exposures and refractoriness. (4) CAR T cell product characteristics. (5) Products that did not meet target dose. (6) Adverse events of grade 3-4. (7) Cytokine release syndrome and ICANS. (8). Maintenance therapy. Supplemental Figures: (1) Study schematic and subject disposition, (2) Correlates of manufacturing success, (3) Hematopoietic recovery, (4) Post-infusion T cell phenotypes, (5) Correlates of in vivo expansion and manufacturing success, (6) Late post-infusion CAR T cell re-expansion, (7) Soluble BCMA, (8) Late-onset clinical responses, (9) MM cell BCMA expression, (10) Pre- and post-treatment Sox2-specific T cell responses in CART-BCMA monotherapy patients, (11) Pre- and post-treatment Sox2-specific T cell responses in CART-BCMA + huCART19 combination therapy patients, (12) Sustained post-treatment SOX2-specific T-cell responses.
Year:
2025
We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-BCMA) with or without anti-CD19 CAR T cells (huCART19) in multiple myeloma (MM) patients responding to third- or later-line therapy (phase A, N = 10) or high-risk patients responding to first-line therapy (phase B, N = 20), followed by early lenalidomide or pomalidomide maintenance. We observed no high-grade cytokine release syndrome (CRS) and only one instance of low-grade neurologic toxicity. Among 15 subjects with measurable disease, 10 exhibited partial response (PR) or better; among 26 subjects responding to prior therapy, 9 improved their response category and 4 converted to minimal residual disease (MRD)–negative complete response/stringent complete response. Early maintenance therapy was safe, feasible, and coincided in some patients with CAR T-cell reexpansion and late-onset, durable clinical response. Outcomes with CART-BCMA + huCART19 were similar to CART-BCMA alone. Collectively, our results demonstrate favorable safety, pharmacokinetics, and antimyeloma activity of dual-target CAR T-cell therapy in early lines of MM treatment. Significance: CAR T cells in early lines of MM therapy could be safer and more effective than in the advanced setting, where prior studies have focused. We evaluated the safety, pharmacokinetics, and efficacy of CAR T cells in patients with low disease burden, responding to current therapy, combined with standard maintenance therapy. This article is highlighted in the In This Issue feature, p. 101
Year:
2025
Collaborators (10)
Alfred Garfall
Assistant Professor, Clinician-Educator
University of Pennsylvania
Edward A. Stadtmauer
University of Pennsylvania
Dan Vogl
Associate Professor of Medicine
University of Pennsylvania
Elizabeth Hexner
Associate Professor, Clinician-Educator
University of Pennsylvania
Carl H. June
Professor
University of Pennsylvania
Joseph A. Fraietta
University of Pennsylvania
Gerald Linette
Professor
University of Pennsylvania
sandra susanibar adaniya
Assistant Professor
University of Pennsylvania
Beatriz M. Carreno
University of Pennsylvania
Adam Cohen
Associate Professor, Clinician-Educator
University of Pennsylvania
Make your next move.
Prepare your application
Review drafts before you send them.